Stay updated with breaking news from Alkermes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ALKS stock, giving a Buy rating yesterday. Chris Shibutani has giv...
Alkermes plc (NASDAQ:ALKS – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The […]
Moody Aldrich Partners LLC lifted its stake in Alkermes plc (NASDAQ:ALKS – Free Report) by 31.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 52,570 shares of the company’s stock after buying an additional 12,496 shares during the quarter. Moody Aldrich Partners LLC’s holdings in Alkermes […]
Moody Aldrich Partners LLC boosted its position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 31.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,570 shares of the company’s stock after purchasing an additional 12,496 shares during […]
ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2 patients is planned for 2nd half of 2024. Jefferies raises price target & probability of success for ALKS-2680.